# AmpliTech Group, Inc.: financial statements, quarterly

AMPG · Nasdaq · CIK 1518461 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ampg.md) · [Financials](/companies/ampg/financials.md) · [Filings](/companies/ampg/filings.md) · [Insiders](/companies/ampg/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ampg/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3.4](/filings/0001493152-24-045943.md) | [4.0 d](/filings/0001641172-25-001715.md) | [2.3](/filings/0001641172-25-010523.md) | [2.5](/filings/0001493152-25-011972.md) | [2.8](/filings/0001493152-25-022459.md) | [1.9 d](/filings/0001493152-26-012914.md) | [3.6](/filings/0001493152-26-022715.md) | [11.0](/filings/0001493152-26-037751.md) | [6.1](/filings/0001493152-25-022459.md) | [4.5 d](/filings/0001493152-26-012914.md) | [5.3](/filings/0001493152-26-022715.md) | [8.1](/filings/0001493152-26-037751.md) |
| Cost of revenue | $m | [1.9](/filings/0001493152-24-045943.md) | [2.0 d](/filings/0001641172-25-001715.md) | [1.4](/filings/0001641172-25-010523.md) | [1.5](/filings/0001493152-25-011972.md) | [1.5](/filings/0001493152-25-022459.md) | [1.7 d](/filings/0001493152-26-012914.md) | [2.4](/filings/0001493152-26-022715.md) | [10.2](/filings/0001493152-26-037751.md) | [3.1](/filings/0001493152-25-022459.md) | [3.5 d](/filings/0001493152-26-012914.md) | [2.8](/filings/0001493152-26-022715.md) | [5.8](/filings/0001493152-26-037751.md) |
| Gross profit | $m | [1.5](/filings/0001493152-24-045943.md) | [2.0 d](/filings/0001641172-25-001715.md) | [0.9](/filings/0001641172-25-010523.md) | [1.1](/filings/0001493152-25-011972.md) | [1.3](/filings/0001493152-25-022459.md) | [0.2 d](/filings/0001493152-26-012914.md) | [1.2](/filings/0001493152-26-022715.md) | [0.9](/filings/0001493152-26-037751.md) | [3.0](/filings/0001493152-25-022459.md) | [1.0 d](/filings/0001493152-26-012914.md) | [2.6](/filings/0001493152-26-022715.md) | [2.3](/filings/0001493152-26-037751.md) |
| Research and development | $m | [0.4](/filings/0001493152-24-045943.md) | [0.7 d](/filings/0001641172-25-001715.md) | [0.3](/filings/0001641172-25-010523.md) | [0.5](/filings/0001493152-25-011972.md) | [0.6](/filings/0001493152-25-022459.md) | [2.3 d](/filings/0001493152-26-012914.md) | [0.7](/filings/0001493152-26-022715.md) | [0.7](/filings/0001493152-26-037751.md) | [0.7](/filings/0001493152-25-022459.md) | [0.6 d](/filings/0001493152-26-012914.md) | [0.5](/filings/0001493152-26-022715.md) | [1.4](/filings/0001493152-26-037751.md) |
| Selling, general and administrative | $m | [2.0](/filings/0001493152-24-045943.md) | [1.8 d](/filings/0001641172-25-001715.md) | [2.0](/filings/0001641172-25-010523.md) | [2.2](/filings/0001493152-25-011972.md) | [1.9](/filings/0001493152-25-022459.md) | [1.8 d](/filings/0001493152-26-012914.md) | [2.3](/filings/0001493152-26-022715.md) | [2.1](/filings/0001493152-26-037751.md) | [2.5](/filings/0001493152-25-022459.md) | [3.7 d](/filings/0001493152-26-012914.md) | [3.7](/filings/0001493152-26-022715.md) | [4.1](/filings/0001493152-26-037751.md) |
| Operating income | $m | [(0.9)](/filings/0001493152-24-045943.md) | [(0.5) d](/filings/0001641172-25-001715.md) | [(1.4)](/filings/0001641172-25-010523.md) | [(1.6)](/filings/0001493152-25-011972.md) | [(1.1)](/filings/0001493152-25-022459.md) | [(4.3) d](/filings/0001493152-26-012914.md) | [(1.9)](/filings/0001493152-26-022715.md) | [(1.9)](/filings/0001493152-26-037751.md) | [(0.2)](/filings/0001493152-25-022459.md) | [(3.3) d](/filings/0001493152-26-012914.md) | [(1.6)](/filings/0001493152-26-022715.md) | [(3.2)](/filings/0001493152-26-037751.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001477932-23-008439.md) | [0.0 d](/filings/0001641172-25-001715.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(0.9)](/filings/0001493152-24-045943.md) | [(0.5) d](/filings/0001641172-25-001715.md) | [(4.7)](/filings/0001641172-25-010523.md) | [(1.6)](/filings/0001493152-25-011972.md) | [(1.2)](/filings/0001493152-25-022459.md) | [(3.8) d](/filings/0001493152-26-012914.md) | [(1.8)](/filings/0001493152-26-022715.md) | [(1.8)](/filings/0001493152-26-037751.md) | [(0.2)](/filings/0001493152-25-022459.md) | [(3.2) d](/filings/0001493152-26-012914.md) | [(1.5)](/filings/0001493152-26-022715.md) | [(3.1)](/filings/0001493152-26-037751.md) |
| Diluted EPS | $ per share | [(0.09)](/filings/0001493152-24-045943.md) | not reported | [(0.48)](/filings/0001641172-25-010523.md) | [(0.16)](/filings/0001493152-25-011972.md) | [(0.12)](/filings/0001493152-25-022459.md) | not reported | [(0.09)](/filings/0001493152-26-022715.md) | [(0.08)](/filings/0001493152-26-037751.md) | [(0.01)](/filings/0001493152-25-022459.md) | not reported | [(0.06)](/filings/0001493152-26-022715.md) | [(0.12)](/filings/0001493152-26-037751.md) |
| Basic EPS | $ per share | [(0.09)](/filings/0001493152-24-045943.md) | not reported | [(0.48)](/filings/0001641172-25-010523.md) | [(0.16)](/filings/0001493152-25-011972.md) | [(0.12)](/filings/0001493152-25-022459.md) | not reported | [(0.09)](/filings/0001493152-26-022715.md) | [(0.08)](/filings/0001493152-26-037751.md) | [(0.01)](/filings/0001493152-25-022459.md) | not reported | [(0.06)](/filings/0001493152-26-022715.md) | [(0.12)](/filings/0001493152-26-037751.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-26) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [5.5](/filings/0001477932-23-008439.md) | [6.7](/filings/0001641172-25-001715.md) | [2.4](/filings/0001493152-24-021616.md) | [1.0](/filings/0001493152-24-032264.md) | [1.1](/filings/0001493152-24-045943.md) | [19.3](/filings/0001493152-26-012914.md) | [4.0](/filings/0001493152-26-012914.md) | [5.0](/filings/0001493152-26-037751.md) | [8.4](/filings/0001493152-25-022459.md) | [5.0](/filings/0001493152-26-037751.md) | [11.8](/filings/0001493152-26-022715.md) | [8.9](/filings/0001493152-26-037751.md) |
| Current assets | $m | [18.1](/filings/0001477932-23-008439.md) | [17.1](/filings/0001641172-25-001715.md) | [12.9](/filings/0001493152-24-021616.md) | [11.7](/filings/0001493152-24-032264.md) | [12.6](/filings/0001493152-24-045943.md) | [28.3](/filings/0001493152-26-012914.md) | [26.8](/filings/0001641172-25-010523.md) | [25.0](/filings/0001493152-25-011972.md) | [21.6](/filings/0001493152-25-022459.md) | [25.1](/filings/0001493152-26-037751.md) | [33.2](/filings/0001493152-26-022715.md) | [31.2](/filings/0001493152-26-037751.md) |
| Total assets | $m | [32.6](/filings/0001477932-23-008439.md) | [31.4](/filings/0001641172-25-001715.md) | [26.9](/filings/0001641172-25-010523.md) | [25.4](/filings/0001493152-24-032264.md) | [27.5](/filings/0001493152-24-045943.md) | [43.2](/filings/0001493152-26-012914.md) | [42.1](/filings/0001493152-26-022715.md) | [48.6](/filings/0001493152-25-011972.md) | [47.2](/filings/0001493152-25-022459.md) | [51.5](/filings/0001493152-26-037751.md) | [59.7](/filings/0001493152-26-022715.md) | [58.5](/filings/0001493152-26-037751.md) |
| Current liabilities | $m | [2.2](/filings/0001477932-23-008439.md) | [1.5](/filings/0001641172-25-001715.md) | [1.6](/filings/0001493152-24-021616.md) | [1.7](/filings/0001493152-24-032264.md) | [2.6](/filings/0001493152-24-045943.md) | [1.5](/filings/0001493152-26-012914.md) | [2.2](/filings/0001641172-25-010523.md) | [8.9](/filings/0001493152-25-011972.md) | [7.6](/filings/0001493152-25-022459.md) | [14.9](/filings/0001493152-26-037751.md) | [7.8](/filings/0001493152-26-022715.md) | [8.3](/filings/0001493152-26-037751.md) |
| Total liabilities | $m | [5.5](/filings/0001477932-23-008439.md) | [4.7](/filings/0001641172-25-001715.md) | [4.7](/filings/0001493152-24-021616.md) | [4.7](/filings/0001493152-24-032264.md) | [7.2](/filings/0001493152-24-045943.md) | [5.7](/filings/0001493152-26-012914.md) | [6.3](/filings/0001641172-25-010523.md) | [12.8](/filings/0001493152-25-011972.md) | [11.4](/filings/0001493152-25-022459.md) | [18.6](/filings/0001493152-26-037751.md) | [11.4](/filings/0001493152-26-022715.md) | [11.8](/filings/0001493152-26-037751.md) |
| Long-term debt | $m | [0.1](/filings/0001477932-23-008439.md) | [0.1](/filings/0001493152-24-012177.md) | [0.1](/filings/0001493152-24-021616.md) | [0.0](/filings/0001493152-24-032264.md) | [1.1](/filings/0001493152-24-045943.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [27.1](/filings/0001493152-24-045943.md) | [26.7](/filings/0001493152-26-012914.md) | [22.2](/filings/0001493152-25-011972.md) | [20.7](/filings/0001493152-25-022459.md) | [20.4](/filings/0001493152-25-022459.md) | [37.5](/filings/0001493152-26-037751.md) | [35.8](/filings/0001493152-26-037751.md) | [35.8](/filings/0001493152-26-037751.md) | [35.8](/filings/0001493152-25-022459.md) | [32.9](/filings/0001493152-26-037751.md) | [48.4](/filings/0001493152-26-037751.md) | [46.8](/filings/0001493152-26-037751.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(509) d](/filings/0001493152-24-045943.md) | [(1,705) d](/filings/0001641172-25-001715.md) | [(1,077)](/filings/0001641172-25-010523.md) | [(1,320) d](/filings/0001493152-25-011972.md) | [(1,732) d](/filings/0001493152-25-022459.md) | [(1,167) d](/filings/0001493152-26-012914.md) | [(2,009)](/filings/0001493152-26-022715.md) | [(2,251) d](/filings/0001493152-26-037751.md) | [(999) d](/filings/0001493152-25-022459.md) | [(3,424) d](/filings/0001493152-26-012914.md) | [(3,141)](/filings/0001493152-26-022715.md) | [(5,538) d](/filings/0001493152-26-037751.md) |
| Capital expenditure | $k | [155 d](/filings/0001493152-24-045943.md) | [41.7 d](/filings/0001641172-25-001715.md) | [1.6](/filings/0001641172-25-010523.md) | [12.1 d](/filings/0001493152-25-011972.md) | [12.8 d](/filings/0001493152-25-022459.md) | [16.5 d](/filings/0001493152-26-012914.md) | [361](/filings/0001493152-26-022715.md) | [126 d](/filings/0001493152-26-037751.md) | [443 d](/filings/0001493152-25-022459.md) | [85.6 d](/filings/0001493152-26-012914.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2022 (2022-03-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [9.6](/filings/0001477932-23-003423.md) | [9.6](/filings/0001493152-24-021616.md) | [9.6](/filings/0001493152-24-032264.md) | [9.7](/filings/0001493152-24-045943.md) | [9.7](/filings/0001641172-25-010523.md) | [9.7](/filings/0001493152-25-011972.md) | [10.0](/filings/0001493152-25-022459.md) | [20.3](/filings/0001493152-26-022715.md) | [21.0](/filings/0001493152-26-037751.md) | [20.6](/filings/0001493152-25-022459.md) | [24.3](/filings/0001493152-26-022715.md) | [25.4](/filings/0001493152-26-037751.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 30,043,887 at 2026-08-11, from the cover of the [10-Q filed 2026-08-13](/filings/0001493152-26-037751.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.